{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:58:07Z","timestamp":1788044287344,"version":"build-2784847793"},"reference-count":25,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"President Foundation of Zhujiang Hospital, Southern Medical University","award":["yzjj2022qn15"],"award-info":[{"award-number":["yzjj2022qn15"]}]},{"name":"Guangdong Medical Science and Technology Research Foundation","award":["A2024149"],"award-info":[{"award-number":["A2024149"]}]},{"name":"Guangdong Medical Science and Technology Research Foundation","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}]},{"name":"Shanghai S&T Innovation Plan","award":["17401970900"],"award-info":[{"award-number":["17401970900"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Cinacalcet, the first FDA-approved calcimimetic agent for treating secondary hyperparathyroidism (SHPT), has unclear factors influencing its therapeutic efficacy in clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To establish a pharmacodynamic model for cinacalcet use in SHPT, analyze drug effect distribution and influencing factors, and determine optimal treatment strategy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched public databases for randomized trials on cinacalcet for SHPT, modeling changes in serum parathyroid hormone (PTH), calcium, and phosphorus postintervention. Key pharmacodynamic parameters and influencing factors were identified, with subgroup analysis for factors not in the covariate model. We also compared cinacalcet efficacy between United States\/European Union (30-180\u2005mg) and Asia (25-100\u2005mg) dosage ranges.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-six studies (4242 subjects) were analyzed. Covariate analysis showed increasing PTH baseline and vitamin D use proportionally affected PTH and calcium decrease. Postintervention, maximum effects were observed with onset times of 0.46, 0.15, and 0.29 months. Subgroup analysis showed factors such as dialysis time, baseline calcium and phosphorus, phosphate binder use, gender proportion, patient ethnicity, blinding, and age influenced PTH, calcium, and phosphorus decrease. The efficacy of cinacalcet at a dosage of 25 to 100\u2005mg in Asian populations was comparable to that observed at a dose range of 30 to 180\u2005mg in Western populations, suggesting that reducing the therapeutic dose of cinacalcet may potentially yield a better benefit\u2013risk ratio.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We established a pharmacokinetic model for cinacalcet in SHPT treatment, providing crucial data for identifying effective patient populations and optimizing treatment strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf021","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T17:57:52Z","timestamp":1743443872000},"source":"Crossref","is-referenced-by-count":3,"title":["Pharmacodynamic Modeling of Cinacalcet in Secondary Hyperparathyroidism: Efficacy and Influencing Factors Analysis"],"prefix":"10.1210","volume":"9","author":[{"given":"Zhizhou","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital, Fudan University , Shanghai, 201508 Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine , Shanghai, 201203 Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University , Guangzhou, 510120 Guangdong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou, 510120 Guangdong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Eighth Affiliated Hospital, Sun Yat-sen University , Shenzhen, 518033 Guangdong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyao","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Nanfang Hospital, Southern Medical University , Guangzhou, 510515 Guangdong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Student Office, The Second Clinical College of Southern Medical University , Guangzhou, 510515 Guangdong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Student Office, The Second Clinical College of Southern Medical University , Guangzhou, 510515 Guangdong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0687-0904","authenticated-orcid":false,"given":"Tingting","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhujiang Hospital, Southern Medical University , Guangzhou, Guangdong 501280 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8816-340X","authenticated-orcid":false,"given":"Xin","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Centre, Zhujiang Hospital, Southern Medical University , Guangzhou, Guangdong 501280 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2923-3206","authenticated-orcid":false,"given":"Lujin","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine , Shanghai, 201203 Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"10302","key":"2025040306513740500_bvaf021-B1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"2025040306513740500_bvaf021-B2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamainternmed.2021.4813","article-title":"Accounting for age in the definition of chronic kidney disease","volume":"181","author":"Liu","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2025040306513740500_bvaf021-B3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.ajkd.2021.05.020","article-title":"Etelcalcetide utilization, dosing titration, and chronic kidney disease-mineral and bone disease (CKD-MBD) marker responses in US hemodialysis patients","volume":"79","author":"Karaboyas","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2025040306513740500_bvaf021-B4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"2025040306513740500_bvaf021-B5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.otc.2023.07.010","article-title":"Secondary hyperparathyroidism","volume":"57","author":"Stack","year":"2024","journal-title":"Otolaryngol Clin North Am"},{"issue":"4","key":"2025040306513740500_bvaf021-B6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2025040306513740500_bvaf021-B7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.01760215","article-title":"Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism","volume":"11","author":"Bover","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025040306513740500_bvaf021-B8","author":"U.S. Food and Drug Administration","year":"2004"},{"key":"2025040306513740500_bvaf021-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.podrm.2017.02.001","article-title":"Cinacalcet hydrochloride","volume":"42","author":"Mostafa","year":"2017","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"2025040306513740500_bvaf021-B10","doi-asserted-by":"crossref","unstructured":"Strippoli GF, Tong A, Palmer SC, Elder G, Craig JC. Calcimimetics for secondary hyperparathyroidism in chronic kidneydisease patients (Review). Cochrane Database Syst Rev. 2006. Doi: 10.1002\/14651858.CD006254","DOI":"10.1002\/14651858.CD006254"},{"issue":"15","key":"2025040306513740500_bvaf021-B11","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"2025040306513740500_bvaf021-B12","doi-asserted-by":"crossref","first-page":"19612","DOI":"10.1038\/srep19612","article-title":"PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism","volume":"6","author":"Akizawa","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"2025040306513740500_bvaf021-B13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2025040306513740500_bvaf021-B14","doi-asserted-by":"crossref","first-page":"e2235060","DOI":"10.1001\/jamanetworkopen.2022.35060","article-title":"Placebo response to oral administration in osteoarthritis clinical trials and its associated factors: a model-based meta-analysis","volume":"5","author":"Wen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2025040306513740500_bvaf021-B15","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s11095-022-03201-5","article-title":"Applications of model-based meta-analysis in drug development","volume":"39","author":"Chan","year":"2022","journal-title":"Pharm Res"},{"issue":"6","key":"2025040306513740500_bvaf021-B16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/clpt.2011.242","article-title":"Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond","volume":"90","author":"Mandema","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2025040306513740500_bvaf021-B17","unstructured":"Yexuan W . 2025. Supplementary Material for Pharmacodynamic Modeling of Cinacalcet in Secondary Hyperparathyroidism Efficacy and Influencing Factors Analysis. Zenodo. 10.5281\/zenodo.14753993."},{"key":"2025040306513740500_bvaf021-B18","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019","edition":"2nd ed"},{"issue":"6","key":"2025040306513740500_bvaf021-B19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.kint.2017.12.014","article-title":"Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial","volume":"93","author":"Floege","year":"2018","journal-title":"Kidney Int"},{"issue":"3","key":"2025040306513740500_bvaf021-B20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Fukagawa","year":"2013","journal-title":"Ther Apher Dial"},{"issue":"3","key":"2025040306513740500_bvaf021-B21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/hdi.12503","article-title":"Hemodialysis practice patterns in the Russia dialysis outcomes and practice patterns study (DOPPS), with international comparisons","volume":"21","author":"Bikbov","year":"2017","journal-title":"Hemodial Int"},{"key":"2025040306513740500_bvaf021-B22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/IJNRD.S124844","article-title":"Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study","volume":"10","author":"Gojaseni","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"5","key":"2025040306513740500_bvaf021-B23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/kisup.2013.91","article-title":"Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan","volume":"3","author":"Fukuma","year":"2013","journal-title":"Kidney Int Suppl (2011)"},{"issue":"11","key":"2025040306513740500_bvaf021-B24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrneph.2013.147","article-title":"FGF-23 and secondary hyperparathyroidism in chronic kidney disease","volume":"9","author":"Silver","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"13","key":"2025040306513740500_bvaf021-B25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s40265-021-01578-y","article-title":"Upacicalcet: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/5\/bvaf021\/62780854\/bvaf021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/5\/bvaf021\/62780854\/bvaf021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T07:41:45Z","timestamp":1743666105000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf021\/8097755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,24]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf021","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,24]]},"article-number":"bvaf021"}}